Drug profile · INN
lamotrigine
APX-LAMOTRIGINE
lamotrigine (APX-LAMOTRIGINE) is a sodium channel alpha subunit blocker. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lamotrigine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 7
- Data quality
- 0.89
Quick answer
lamotrigine (APX-LAMOTRIGINE) is a sodium channel alpha subunit blocker. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is lamotrigine?
lamotrigine (APX-LAMOTRIGINE) is a sodium channel alpha subunit blocker. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lamotrigine?
APX-LAMOTRIGINE is a marketed brand name for lamotrigine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lamotrigine?
lamotrigine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.